Germany · Delayed Price · Currency is EUR Capricor Therapeutics Statistics
Total Valuation
FRA:4LN2 has a market cap or net worth of EUR 261.52 million. The enterprise value is 189.25 million.
| Market Cap | 261.52M |
| Enterprise Value | 189.25M |
Important Dates
The next estimated earnings date is Friday, February 27, 2026.
| Earnings Date | Feb 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 45.72M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +43.02% |
| Shares Change (QoQ) | +0.02% |
| Owned by Insiders (%) | 1.28% |
| Owned by Institutions (%) | 31.90% |
| Float | 40.19M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 27.57 |
| PB Ratio | 3.66 |
| P/TBV Ratio | 3.66 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -2.71 |
| EV / Sales | 19.77 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -3.25 |
Financial Position
The company has a current ratio of 3.59, with a Debt / Equity ratio of 0.17.
| Current Ratio | 3.59 |
| Quick Ratio | 3.50 |
| Debt / Equity | 0.17 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.21 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -107.79% and return on invested capital (ROIC) is -64.37%.
| Return on Equity (ROE) | -107.79% |
| Return on Assets (ROA) | -49.39% |
| Return on Invested Capital (ROIC) | -64.37% |
| Return on Capital Employed (ROCE) | -88.19% |
| Revenue Per Employee | 59,291 |
| Profits Per Employee | -436,749 |
| Employee Count | 160 |
| Asset Turnover | 0.10 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -75.31% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -75.31% |
| 50-Day Moving Average | 5.34 |
| 200-Day Moving Average | 7.69 |
| Relative Strength Index (RSI) | 43.17 |
| Average Volume (20 Days) | 60 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 8.92 |
Income Statement
In the last 12 months, FRA:4LN2 had revenue of EUR 9.49 million and -69.88 million in losses. Loss per share was -1.54.
| Revenue | 9.49M |
| Gross Profit | -55.18M |
| Operating Income | -73.88M |
| Pretax Income | -69.88M |
| Net Income | -69.88M |
| EBITDA | -72.38M |
| EBIT | -73.88M |
| Loss Per Share | -1.54 |
Balance Sheet
The company has 84.01 million in cash and 12.39 million in debt, giving a net cash position of 71.61 million.
| Cash & Cash Equivalents | 84.01M |
| Total Debt | 12.39M |
| Net Cash | 71.61M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 71.48M |
| Book Value Per Share | 1.56 |
| Working Capital | 62.05M |
Cash Flow
In the last 12 months, operating cash flow was -52.03 million and capital expenditures -6.25 million, giving a free cash flow of -58.28 million.
| Operating Cash Flow | -52.03M |
| Capital Expenditures | -6.25M |
| Free Cash Flow | -58.28M |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | -778.80% |
| Pretax Margin | -736.62% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
FRA:4LN2 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -43.02% |
| Shareholder Yield | -43.02% |
| Earnings Yield | -26.72% |
| FCF Yield | -22.28% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on June 5, 2019. It was a reverse split with a ratio of 0.1.
| Last Split Date | Jun 5, 2019 |
| Split Type | Reverse |
| Split Ratio | 0.1 |
Scores
FRA:4LN2 has an Altman Z-Score of 3.27 and a Piotroski F-Score of 1.
| Altman Z-Score | 3.27 |
| Piotroski F-Score | 1 |